GlaxoSmithKline (GSK) has agreed to acquire Sierra Pharma for US$55 per share, representing a total transaction value of US$1.9 B. With the deal, GSK gains access to Sierra’s lead candidate, momelotinib, which is indicated in patients with myelofibrosis. In January 2021, results from a Phase III trial demonstrated the drugs’ ability in reducing disease symptoms and dependence on blood transfusions, making it a superior therapeutic choice over the current standard of care. With the deal, GSK also gains a shot at expanding its pipeline with two additional early-stage assets, SRA515 and SRA737.